Rectal Cancer Neoadjuvant Therapy Decision
Evolving Paradigm
Treatment of rectal cancer is diverging based on tumor location relative to the APR:
Upper Rectal Tumors (Above APR)
- Intraperitoneal location
- Lower incidence of MRF/organ involvement (wider pelvis)
- No LPLN metastasis risk
- Potential for T4a (peritoneal spread)
- Increasingly treated with upfront surgery (like sigmoid tumors)
- OCUM trial: 89% went to surgery, no LR at 3 years
- Exception: posterior/lateral MRF involvement → may still need nCRT
Lower Rectal Tumors (Below APR)
- Extraperitoneal location
- Higher incidence of MRF/organ involvement (tapering mesorectal fat)
- LPLN metastasis risk (T3/T4)
- Higher incidence of pulmonary metastasis (systemic drainage via middle rectal veins)
- Generally require nCRT or total neoadjuvant therapy (TNT)
Key Principle: Anatomy Over Stage
Board Pearl
Anatomic factors — primarily MRF involvement — rather than T and N categories are the key determinants of local recurrence and need for nCRT. This is a radical departure from previous guidelines where nCRT was recommended for ALL stage II and III rectal cancers.
Role of nCRT
- Primary impact: Reduces local recurrence by 50%
- Little or no effect on overall survival or disease-free survival
- Currently deployed based on T and N category, but its true benefit is in tumors threatening the surgical margin
- For T3N+ upper rectal tumors with widely clear MRF → LR rates of 2.3-3% with surgery alone (comparable to nCRT + surgery)
Mesorectal Lymph Nodes and nCRT
- OCUM, QuickSilver, and MERCURY studies: mesorectal lymph nodes assessed at MRI have no impact on LR
- Lymph node involvement causes decline in overall survival but with rare exceptions has no impact on MRF involvement and hence LR rates
- This means N+ alone should not automatically trigger nCRT in upper rectal tumors with clear MRF
Total Neoadjuvant Therapy (TNT)
- Chemotherapy administered in the neoadjuvant setting along with nCRT
- Reserved for a subset of lower rectal tumors
- High-risk features: T4, EMVI, threatened MRF, LPLN metastasis
High-Risk Features Driving nCRT/TNT
- MRF involvement or threatened MRF (<1 mm)
- T4 tumors
- Extramural Vascular Invasion
- Tumor Deposits near MRF
- Lateral Pelvic Lymph Nodes metastasis (>=7 mm pretreatment)
- Sphincter involvement requiring APR